scholarly article | Q13442814 |
P50 | author | Ertan Mayatepek | Q88240251 |
P2093 | author name string | Markus Vogel | |
Thomas Hoehn | |||
Ortwin Adams | |||
Alexander Kovacevic | |||
Linda Bonzel | |||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | respiratory syncytial virus | Q1052913 |
P304 | page(s) | 185-188 | |
P577 | publication date | 2010-07-01 | |
P1433 | published in | Clinical Infectious Diseases | Q5133764 |
P1476 | title | Palivizumab-resistant human respiratory syncytial virus infection in infancy | |
P478 | volume | 51 |
Q34542805 | A cell based high-throughput screening approach for the discovery of new inhibitors of respiratory syncytial virus |
Q54232019 | Complete Genome Sequence of an ON1 Human Respiratory Syncytial Virus Strain Isolated in Lebanon in 2015. |
Q42275949 | Cross-neutralization of four paramyxoviruses by a human monoclonal antibody |
Q92360246 | Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B |
Q64121419 | Detection of ON1 and novel genotypes of human respiratory syncytial virus and emergence of palivizumab resistance in Lebanon |
Q42251545 | Detection of respiratory syncytial virus fusion protein variants between 2009 and 2012 in China |
Q64054630 | Emergence of new antigenic epitopes in the glycoproteins of human respiratory syncytial virus collected from a US surveillance study, 2015–17 |
Q37732535 | Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein |
Q30375062 | GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process |
Q39460933 | Genetic variability of subgroup A and B respiratory syncytial virus strains circulating in southwestern China from 2009 to 2011. |
Q30148692 | Global epidemiology of non-influenza RNA respiratory viruses: data gaps and a growing need for surveillance |
Q28483402 | High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery |
Q28245563 | Identification of nucleolin as a cellular receptor for human respiratory syncytial virus |
Q37997822 | Identifying targets in the hunt for effective respiratory syncytial virus interventions |
Q38387416 | Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis |
Q35845854 | Molecular evolution of respiratory syncytial virus fusion gene, Canada, 2006-2010. |
Q33860620 | NEP: web server for epitope prediction based on antibody neutralization of viral strains with diverse sequences |
Q40059727 | Neutralizing epitopes of RSV and palivizumab resistance in Japan |
Q30413158 | Passive immune neutralization strategies for prevention and control of influenza A infections |
Q28287657 | RSV fusion: time for a new model |
Q37123109 | Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains |
Q45325102 | Respiratory Syncytial Virus (RSV): Targeting the G Protein Provides a New Approach for an Old Problem. |
Q58595178 | Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge |
Q39719279 | Respiratory syncytial virus prevention in children with congenital heart disease: who and how? |
Q45359023 | Selection and characterization of human respiratory syncytial virus escape mutants resistant to a polyclonal antiserum raised against the F protein |
Q28272863 | The RSV fusion receptor: not what everyone expected it to be |
Q55447639 | The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics. |
Q47549703 | Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses |
Search more.